Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Harris A. Ahmad"'
Autor:
Harris A. Ahmad, James E. East, Remo Panaccione, Simon Travis, James B. Canavan, Keith Usiskin, Michael F. Byrne
Publikováno v:
Intestinal Research, Vol 21, Iss 3, Pp 283-294 (2023)
Inflammatory bowel disease encompasses Crohn’s disease and ulcerative colitis and is characterized by uncontrolled, relapsing, and remitting course of inflammation in the gastrointestinal tract. Artificial intelligence represents a new era within t
Externí odkaz:
https://doaj.org/article/fdfe0c4054d64bcb9ff209ee4dac87af
Publikováno v:
BMC Rheumatology, Vol 6, Iss 1, Pp 1-9 (2022)
Abstract Background Rheumatoid arthritis (RA) is a heterogeneous disease with established poor prognostic factors such as seropositivity, joint damage, and high disease activity at an early, treatment-naïve stage of disease. However, few studies hav
Externí odkaz:
https://doaj.org/article/cfff0a181af94cbfae12b02885e3f124
Autor:
Harris A. Ahmad, Joshua F. Baker, Philip G. Conaghan, Paul Emery, Thomas W. J. Huizinga, Yedid Elbez, Subhashis Banerjee, Mikkel Østergaard
Publikováno v:
Arthritis Research & Therapy, Vol 24, Iss 1, Pp 1-11 (2022)
Abstract Background Drug-free remission is a desirable goal in rheumatoid arthritis (RA) for both patients and clinicians. The aim of this post hoc analysis was to investigate whether clinical and magnetic resonance imaging (MRI) variables in patient
Externí odkaz:
https://doaj.org/article/2097c33bc9ac417d9da931569cfaa16c
Autor:
Raymond K. Cross, Jenny S. Sauk, Joe Zhuo, Ryan W. Harrison, Samantha J. Kerti, Kelechi Emeanuru, Jacqueline O’Brien, Harris A. Ahmad, Antoine G. Sreih, Joehl Nguyen, Sara N. Horst, David Hudesman
Publikováno v:
Gastro Hep Advances, Vol 1, Iss 6, Pp 927-935 (2022)
Background and Aims: This study aimed to evaluate associations between disease severity, patient-reported outcomes (PROs), and work productivity in patients with inflammatory bowel disease (IBD [Crohn’s disease (CD) and ulcerative colitis (UC)]). M
Externí odkaz:
https://doaj.org/article/a966b9317578497aac871332a9cb970d
Autor:
Vibeke Strand, Evo Alemao, Thomas Lehman, Alyssa Johnsen, Subhashis Banerjee, Harris A. Ahmad, Philip J. Mease
Publikováno v:
Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-11 (2018)
Abstract Background To explore the effect of abatacept treatment on patient-reported outcomes (PROs) in psoriatic arthritis (PsA). Methods Patients with PsA were randomised (1:1) to subcutaneous abatacept 125 mg weekly/placebo for 24 weeks with early
Externí odkaz:
https://doaj.org/article/3f7b9386ce994ffb83cc3434ef5ac956
Autor:
Yannick Degboé, Michael Schiff, Michael Weinblatt, Roy Fleischmann, Harris A. Ahmad, Arnaud Constantin
Publikováno v:
Journal of Clinical Medicine, Vol 9, Iss 6, p 2017 (2020)
To date, the impact of background glucocorticoids (GC) on the efficacy and safety of abatacept or adalimumab in patients with active rheumatoid arthritis (RA) is not clearly established. This post hoc analysis of (AMPLE) trial (NCT00929864) compared
Externí odkaz:
https://doaj.org/article/33c2509eb96943c282239e50a41cc67b
Autor:
Philip J Mease, Iain B McInnes, Gianfranco Ferraccioli, Maria-Antonietta D'Agostino, Manuela Le Bars, Subhashis Banerjee, Harris A Ahmad, Yedid Elbez
Publikováno v:
RMD Open, Vol 5, Iss 1 (2019)
Objective This post hoc analysis of the phase III Active PSoriaTic Arthritis RAndomizEd TriAl (ASTRAEA) evaluated the effect of baseline body mass index (BMI) on subsequent response to subcutaneous (SC) abatacept in patients with psoriatic arthritis
Externí odkaz:
https://doaj.org/article/69a3fb4c228142e5a9be23c0e20a6497
Autor:
Mathieu Uzzan, Yoram Bouhnik, Maria Abreu, Harris A Ahmad, Shashi Adsul, Hilde Carlier, Marla Dubinsky, Matthew Germinaro, Vipul Jairath, Irene Modesto, Eric Mortensen, Neeraj Narula, Ezequiel Neimark, Alessandra Oortwijn, Marijana Protic, David T Rubin, Young S Oh, Jolanta Wichary, Laurent Peyrin-Biroulet, Walter Reinisch
Publikováno v:
Journal of Crohn's and Colitis.
BackgroundRates of enrolment in clinical trials in inflammatory bowel disease [IBD] have decreased dramatically in recent years. This has led to delays, increased costs and failures to develop novel treatments.AimsThe aim of this work is to describe
Autor:
Bruce E. Sands, Anjali Jain, Harris A. Ahmad, Mark Osterman, Arteid Memaj, James B. Canavan, Jordan Axelrad
Publikováno v:
American Journal of Gastroenterology. 117:e593-e594
Autor:
Anita Afzali, Axel Dignass, Monika Fischer, Charles Sninsky, Alessandro Armuzzi, Chun Wu, Harris A. Ahmad, Arteid Memaj, Sarah Harris, James B. Canavan, Stefan Schreiber
Publikováno v:
American Journal of Gastroenterology. 117:e513-e514